Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

EU to decide on $52 billion AbbVie, Shire deal by Oct. 16

Published 15/09/2014, 15:13
© Reuters A sign sits in front of Shire's manufacturing facility in Lexington, Massachusetts
LLY
-
NOVN
-
SHP
-
ZBH
-
ABBV
-

BRUSSELS (Reuters) - European Union competition regulators will decide by Oct. 16 whether to clear U.S. drugmaker AbbVie's (N:ABBV) 32 billion pounds (51.99 billion U.S. dollar) bid for Irish peer Shire Plc (L:SHP), the European Commission said on Monday.

The deal will help Chicago-based AbbVie cut both its U.S. tax bill and its dependence on its top-selling arthritis drug Humira which will lose its patent protection in 2016.

The EU antitrust authority can either clear the deal unconditionally or demand concessions if it sees potential competition issues resulting from the takeover.

The deal is the latest consolidation in the pharmaceutical industry. The Commission is now reviewing a bid by U.S. drugmaker Eli Lilly (N:LLY) for Swiss peer Novartis (VX:NOVN), and U.S. orthopaedic products maker Zimmer Holdings' (N:ZMH) offer for Biomet Inc [LVBHAB.UL].

(Reporting by Foo Yun Chee)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.